CD47 Targeting Therapeutics Market Global Forecasts, 2021-2035, Featuring Abpro, Apmonia Therapeutics, Bristol Myers Squibb, ImmuneOncia Therapeutics and KAHR Medical

DUBLIN, Dec. 24, 2021 /PRNewswire/ — The “CD47 Targeting Therapeutics Market by Target Disease Indication, Type of Molecule Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035” report has been added to ResearchAndMarkets.com’s offering.

Research and Markets Logo

The  report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of CD47 targeting therapeutics in the healthcare industry, over the next 15 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with CD47 targeting therapeutics developers, over the next 15 years. The report has provided an informed estimate of the market’s evolution, during the period 2021-2035, based on several relevant parameters, such as adoption trends, and expected price variations for these products.

The report features the likely distribution of the current and forecasted opportunity within the CD47 targeting therapeutics market across

  • [A] target disease indication (acute myeloid leukemias, non-Hodgkin lymphoma, colorectal cancers, diffuse large b-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral muscositis, small cell lung cancers),
  • [B] type of molecule (biologics and small molecules),
  • [C] key players and
  • [D] key geographical regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel).

In order to account for future uncertainties and to add robustness to the model, the report has provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Key Questions Answered

  • Who are the leading players engaged in the development of CD47 targeting therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which companies are actively involved in conducting clinical trials for their therapeutics?
  • What is the evolving trend related to the focus of publications related to CD47 targeting therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders/experts in this field?
  • What are the evolving social media trends related to CD47 targeting therapeutics?
  • What are the different initiatives undertaken by big pharma players for the development of CD47 therapeutics in the recent past?
  • How is the current and future opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Historical Events related to CD47 Targeting Therapies
3.3. Application Areas
3.4. Mechanism of Action
3.5. Associated Side Effects and Likely Solutions
3.6. Key Features
3.7. Target Indications
3.8. Future Outlook

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CD-47 Targeting Therapeutics: Market Landscape
4.3. CD-47 Therapeutics: Developer Landscape

5. COMPANY PROFILES
5.1. Abpro
5.3. Apmonia Therapeutics
5.4. Arch Oncology
5.5. Aurigene
5.6. Bristol Myers Squibb
5.7. EpicentRx
5.8. Forty Seven
5.9. ImmuneOncia Therapeutics
5.10. ImmuneOnco Biopharmaceuticals
5.11. Innovent Biologics
5.12. KAHR Medical
5.13. Light Chain Bioscience
5.14. Morphiex
5.15. Trillium Therapeutics

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CD-47 Targeting Therapeutics: List of Clinical Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Registration Year
6.3.3. Analysis by Trial Status and Trial Registration Year
6.3.4. Analysis by Number of Patients Enrolled and Phase of Development
6.3.5. Analysis by Type of Sponsor
6.3.6. Analysis by Target Patient Group
6.3.7. Analysis by Study Type
6.3.8. Analysis by Type of Masking
6.3.9. Analysis by Type of Interventional Model
6.3.10. Analysis by Primary Purpose of Trial
6.3.11. Analysis of Enrolled Patient Population by Geography

7. PUBLICATION ANALYSIS

8. PARTNERSHIPS AND COLLABORATIONS
8.1. CD-47 Therapeutics: List of Partnerships and Collaborations

9. FUNDING AND INVESTMENTS
9.1. CD-47 Therapeutics: List of Funding and Investments

10. KEY OPINION LEADERS
10.1. CD-47 Therapeutics: List of Key Opinion Leaders

11. EMERGING TRENDS ON SOCIAL MEDIA
11.1. Chapter Overview
11.2. CD-47 Therapeutics: Trends on Twitter
11.2.1. Historical Trend in Volume of Tweets
11.2.2. Trending Words / Phrases on Twitter
11.2.3. Most Popular Drugs on Twitter
11.2.4. Most Prolific Authors on Twitter
11.2.5. Most Popular Indications

12. COMPANY COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Methodology and Key Parameters
12.3. CD-47 Therapy Developers

13. BIG PHARMA PLAYERS

14. START-UP HEALTH INDEXING

15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Global CD-47 Targeting Therapeutics Market, 2021-2035
15.5. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Target Indication
15.6. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Type of Molecule
15.7. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Geography
15.8. Drug-wise Sales Forecast

16. APPENDIX 1: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/d3iga

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:https://www.prnewswire.com/news-releases/cd47-targeting-therapeutics-market-global-forecasts-2021-2035-featuring-abpro-apmonia-therapeutics-bristol-myers-squibb-immuneoncia-therapeutics-and-kahr-medical-301450715.html

SOURCE Research and Markets

CD47 Targeting Therapeutics Market Global Forecasts, 2021-2035, Featuring Abpro, Apmonia Therapeutics, Bristol Myers Squibb, ImmuneOncia Therapeutics and KAHR Medical WeeklyReviewer

PR Newswire Science News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

Avatar of World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer